Lake Street assumed coverage of P3 Health Partners (PIII) with a Buy rating and $20 price target Despite first half revenue declining versus the prior year, Q2 results showed “encouraging signs,” the analyst tells investors. 2025 remains a transitional year as the P3 sets up for a “transformational 2026,” the analyst added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PIII: